Nulojix
belatacept · Bristol-Myers Squibb Pharma EEIG
AUTHORISED IN THE EUWhat Nulojix is used for
Nulojix, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Nulojix
- Active substance
- belatacept
- Disease area
- Graft Rejection; Kidney Transplantation
- Medicine group
- Immunosuppressants
- ATC code
- L04AA28
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2011
Official information
In the USA
Same active substance: Nulojix
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Nulojix used for?
Nulojix, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
What is the active substance in Nulojix?
Nulojix contains belatacept.
Who makes Nulojix?
The EU marketing authorisation holder is Bristol-Myers Squibb Pharma EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU